Efficacy of B Cell Depletion Therapy with Rituximab in Refractory Chronic Recurrent Uveitis Associated with Vogt-Koyanagi-Harada Disease
Efficacy of B Cell Depletion Therapy with Rituximab in Refractory Chronic Recurrent Uveitis Associated with Vogt-Koyanagi-Harada Disease
复制标题
DOI：
10.1080/09273948.2020.1820531
复制
发表时间：
2020-09-27
影响因子：
3.3
通讯作者：
Opdenakker, Ghislain
中科院分区：
文献类型：
--
作者：
Abu El-Asrar, Ahmed M.;Dheyab, Abdulsalam;Opdenakker, Ghislain
目的评价鼠/人嵌合抗CD 20单克隆抗体利妥昔单抗去除B细胞治疗Vogt-Koyanagi-Harada（VKH）病相关的难治性慢性复发性肉芽肿性葡萄膜炎的疗效。方法回顾性分析9例（18眼）常规联合免疫抑制治疗无效的青光眼患者的临床资料。结果所有患者均接受3次美罗华静脉滴注。开始利妥昔单抗治疗后的随访期为9至36个月（平均值+/- SD，19.2 +/- 10.1）。所有患者均获得缓解，视力显著改善（p<0.001）。利妥昔单抗在控制炎症的同时提供了皮质类固醇节约效应沿着。未观察到利妥昔单抗相关并发症。结论利妥昔单抗治疗难治性慢性复发性肉芽肿性葡萄膜炎合并VKH病有效。
Purpose To evaluate the efficacy of B cell depletion therapy with the chimeric mouse/human anti-CD20 monoclonal antibody rituximab for refractory chronic recurrent granulomatous uveitis associated with Vogt-Koyanagi-Harada (VKH) disease. Methods Retrospective study of 9 patients (18 eyes) who failed to respond to conventional combination immunosuppressive therapy. Results All the patients received 3 rituximab infusions. The follow-up period after initiation of rituximab therapy ranged from 9 to 36 months (mean +/- SD, 19.2 +/- 10.1). All patients achieved remission and visual acuity significantly improved (p< .001). Rituximab provided corticosteroid-sparing effect along with control of inflammation. No rituximab-related complications were observed. Conclusions Rituximab is effective for the treatment of refractory chronic recurrent granulomatous uveitis associated with VKH disease.